Walleye Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Walleye Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.71K	Sell	600 -46,400	-99%	-$360K	﹤0.01%	4192
2025 Q4	$367K	Buy	+47,000	New	+$340K	﹤0.01%	3159
2025 Q3	–	Sell	-3,000	Closed	-$26.9K	–	4497
2025 Q2	$26.9K	Buy	+3,000	New	+$27.9K	﹤0.01%	4189
2025 Q1	–	Sell	-3,000	Closed	-$22.6K	–	4266
2024 Q4	$22.6K	Sell	3,000 -100	-3%	-$759	﹤0.01%	4487
2024 Q3	$23.6K	Buy	+3,100	New	+$23.6K	﹤0.01%	4785
2024 Q2	–	Sell	-7,000	Closed	-$35.6K	–	5589
2024 Q1	$35.6K	Buy	+7,000	New	+$39.4K	﹤0.01%	4781
2023 Q3	–	Sell	-5,300	Closed	-$37.3K	–	4870
2023 Q2	$37.3K	Sell	5,300 -13,000	-71%	-$104K	﹤0.01%	3693
2023 Q1	$153K	Sell	18,300 -21,100	-54%	-$203K	﹤0.01%	2677
2022 Q4	$452K	Buy	39,400 +1,600	+4%	+$20K	0.01%	1517
2022 Q3	$476K	Buy	+37,800	New	+$486K	0.01%	1511

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Walleye Capital's BCRX Position: Q1 2026 in Review

Walleye Capital reduced its BioCryst Pharmaceuticals (BCRX) stake by 89% in Q1 2026, selling an estimated $1.75M and leaving 26,793 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #3178.

Walleye Capital first reported a position in BCRX in Q4 2019 and has held it in 21 quarters since. The position peaked at $20.6M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Walleye Capital held 26,793 shares of BioCryst Pharmaceuticals worth $255K as of Q1 2026.
Walleye Capital sold 224,877 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $1.75M.
BioCryst Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3178 holding.
Walleye Capital first reported a position in BioCryst Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
Walleye Capital's BioCryst Pharmaceuticals position peaked at $20.6M in Q2 2025.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.